Letter of Cross-Reference. Promptly, but no later than [***], after the Effective Date, Genentech shall provide to Corvus a letter of cross-reference authorizing Corvus to reference certain information previously provided by Genentech in its INDs for the Genentech Molecule as support for the Combination portion of the Study in accordance with 21 CFR § 312.23(b). Such letter of cross-reference shall remain in full force and effect unless it is withdrawn by Genentech due to termination of this Agreement by a Party.
Appears in 4 contracts
Samples: Phase I/Ib Combination Study Agreement (Corvus Pharmaceuticals, Inc.), Phase I/Ib Combination Study Agreement (Corvus Pharmaceuticals, Inc.), Phase I/Ib Combination Study Agreement (Corvus Pharmaceuticals, Inc.)
